Hydralazine 25mg tablets (pack of 56)

Hydralazine 25 mg Tablets

The active ingredient is 1-hydrazinophthalazine hydrochloride (hydralazine hydrochloride).

One coated tablet contains 25 mg hydralazine hydrochloride B.P.

Pale yellow, round, biconvex sugar-coated tablets. One side is marked "GF" in brown ink.

Therapeutic indications
For the treatment of moderate to severe hypertension as an adjunct to other anti-hypertensive agents.

Due to the complementary mechanism of action the combination of hydralazine with b-blockers and diuretics may enable antihypertensive efficacy at lower dose levels and counteract accompanying hydralazine effects such as reflex tachycardia and oedema.

As supplementary medication for use in combination with long-acting nitrates in moderate to severe chronic congestive cardiac failure in patients in whom optimal doses of conventional therapy have proved insufficient.

Posology and method of administration
Posology

Elderly:

Clinical evidence would indicate that no special dosage regime is necessary. Advancing age does not affect either blood concentration or systemic clearance.

Renal elimination may however be affected in so far as kidney function diminishes with age.

Adults:

Hypertension: the dose should be adjusted to the individual requirements of the patient. Treatment should begin with low doses of Apresoline which, depending on the patient's response should be increased stepwise to achieve optimal therapeutic effect whilst keeping unwanted effects to a minimum.

Initially 25 mg bid. This can be increased gradually to a dose not exceeding 200 mg daily. The dose should not be increased beyond 100 mg daily without first checking the patient's acetylator status.

Chronic congestive heart failure: Treatment with Apresoline should always be initiated in hospital, where the patient's individual haemodynamic values can be reliably determined with the help of invasive monitoring. It should then be continued in hospital until the patient has become stabilised on the requisite maintenance dose. Doses vary greatly between individual patients and are generally higher than those used for treating hypertension. After progressive titration (initially 25 mg tid or qid increasing every second day) the maintenance dosage averages 50-75 mg qid.

Paediatric population:

Not recommended

Method of administration

For Oral use only.